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ABSTRACT
Purpose: We aimed to determine and compare the predictive values of depth of 
response (DpR) and early tumor shrinkage (ETS) on long-term outcomes in gastric 
cancer patients treated with trastuzumab. 
Results: From a total of 368 computed tomography examinations, DpR and ETS 
were evaluated. DpR was a significant tumor-size metric in predicting PFS and OS, 
and showed better discriminatory ability (higher Cτ indices, 0.6957 for PFS; 0.7191 
for OS) than ETS. DpR ≥ 45% (vs. < 45%) was the optimal cutoff value, as it was 
best able to identify patients with longer PFS (median 9.0 vs. 6.3 months, hazard 
ratio [HR] = 0.608; 95% confidence interval [CI]: 0.335 to 1.104; P = 0.102) and OS 
(median 23.5 vs. 13.1 months, HR = 0.441; 95% CI: 0.203 to 0.955; P = 0.038). 
Materials and Methods: Sixty-one gastric cancer patients who received first-line 
trastuzumab-based chemotherapy were assessed for DpR and ETS. We employed 
Kaplan-Meier estimates, log-rank tests, Cox proportional hazards regression models, 
time-dependent receiver operating characteristics, and Youden’s J index to evaluate 
and determine cutoff values of DpR and ETS as predictors of progression-free survival 
(PFS) and overall survival (OS). 
Conclusions: DpR and ETS were significant predictors of long-term outcomes in 
gastric cancer patients treated with first-line trastuzumab. Validation in prospective 
trials with larger patient populations is needed.
INTRODUCTION
Gastric cancer, the second leading cause of cancer-
related deaths worldwide, remains a major health problem 
despite a global decrease in its incidence [1]. Currently, 
trastuzumab-based first-line treatments represent the 
standard approach for human epidermal growth factor 
receptor 2 (HER2)-positive advanced gastric cancer (AGC) 
patients [2]; however, it is not equally effective in all such 
patients. Although identifying patients who will most benefit 
from this treatment is paramount, clinically applicable 
surrogate markers for survival have not been properly 
evaluated in AGC patients treated with trastuzumab. Even 
as HER2 gene amplification was reported to predict overall 
survival (OS) in AGC patients undergoing trastuzumab-
based chemotherapy [3], HER2 gene amplification is not 
usually tested in patients who receive a score of 3+ on 
HER2 immunohistochemistry (IHC). 
Defining appropriate surrogate end-points that 
predict long-term survival in prospective studies is 
important in the field of oncology. Aside from well-known 
surrogate end-points for OS, such as progression-free 
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survival (PFS) and objective response rate, other metrics 
based on tumor size have recently been investigated. These 
include early tumor shrinkage (ETS) and depth of response 
(DpR), both of which are indicators of the percentage 
change in tumor size at a designated time point from the 
baseline. ETS, defined as change in tumor size at the 
time of first response evaluation, has been proposed to be 
associated with long-term outcomes in various cancer types 
and regimens, mainly colorectal cancer [4–10]. Recently, 
the concept of DpR [11], defined as the maximal tumor 
shrinkage observed [12], has gained attention in colorectal 
cancer patients treated with cetuximab or bevacizumab. 
Increased DpR was observed to significantly correlate with 
post-progression survival (PPS) or OS in cetuximab- or 
bevacizumab-treated colorectal cancer patients in large 
phase III trials [11, 13, 14]. Analysis of tumor-size metrics 
in association with survival has never been performed 
for gastric cancer. HER2-positive gastric cancers, which 
usually metastasize to measurable lesions in lymph nodes 
or the liver [3, 15] are an ideal system in which to test the 
usage of DpR or ETS as surrogate markers for long-term 
outcome. Additionally, while there have been separate 
studies on the association of DpR or ETS and cancer 
patient prognosis, there has been no study evaluating DpR 
or ETS as predictive factors for survival outcome within 
one treatment cohort, particularly in gastric cancer patients.
The purpose of this study was to investigate the 
predictive values of DpR and ETS on long-term outcomes in 
AGC patients treated with trastuzumab-based chemotherapy. 
We also sought to perform our investigation by using tumor-
size metrics as surrogate markers and defining discriminatory 
cutoff values for dichotomizing patient populations according 
to DpR or ETS to guide treatment planning.
RESULTS
Patients
A total of 61 of 88 gastric cancer patients treated with 
trastuzumab were eligible for this study (Supplementary 
Figure 1). Patients underwent trastuzumab treatment 
between December 2005 and March 2014, with a median 
follow-up duration of 24.3 months (interquartile range, 18.3 
to 28.3 months). The main clinicopathological features and 
response data are shown in Table 1. HER2/CEP17 ratio 
by SISH or FISH was categorized into two groups using 
a cutoff of 4.7, a previously reported cutoff value that 
predicted response and survival [3]. The median number of 
trastuzumab cycles administered was eight (range, 2 to 38).
Comparing DpR with ETS in predicting long-
term outcomes
Relative tumor sizes compared to the baseline (the 
sum of the longest diameters according to RECIST) at 
the first evaluation (ETS) and at the best response (DpR) 
were evaluated from a total of 368 CT examinations 
(see Figure 1 for schematic illustration of tumor size 
metrics). The median time between the first trastuzumab 
administration and the first response evaluation (time 
to ETS) was 6 weeks (interquartile range, 5.3 to 7.1 
weeks). In a univariate analysis, Eastern Cooperative 
Oncology Group (ECOG) performance status and HER2 
overexpression as determined by IHC were significantly 
related to PFS and OS. Among the tumor size metrics, 
DpR was most strongly associated with both PFS and OS 
(P < 0.001), followed by time to tumor growth (TTG) 
and ETS (Supplementary Table 1). A multivariable 
Cox proportional hazards model for patient prognosis, 
adjusted for potential confounding factors including age, 
ECOG performance status, and HER2 overexpression, 
showed that DpR and ETS were significant predictors of 
long-term outcomes of both PFS and OS (Table 2 and 
Supplementary Table 2). 
Comparing the predictive accuracies of DpR 
and ETS as continuous variables for long-term 
outcomes
Time-dependent receiver operating characteristics 
(TDROC) analysis was performed to compare the 
predictive accuracy of DpR and ETS as continuous 
variables for long-term outcomes (Table 3). DpR showed 
better discriminatory ability (higher C
τ
 indices, 0.6957 
[95% CI: 0.6564 to 0.8176] for PFS; 0.7191 [95% CI: 
0.6694 to 0.8465] for OS) than ETS (C
τ
 indices, 0.6722 
[95% CI: 0.6131 to 0.7807] for PFS; 0.6681 [95% CI: 
0.6040 to 0.7952] for OS). Higher C
τ
 indices were found 
for DpR than for ETS consistently for both PFS and OS 
over time (Figure 2). Time-specific accuracy decreased 
minimally over time for OS with both DpR and ETS 
(Figure 2D) yet appeared consistent in the TDROC curves 
of DpR and PFS (Figure 2B). 
Clinical applicability of DpR and ETS
Choice of cutoff values 
The clinical utility of tumor-size metrics often 
involves dichotomization of the population around a cutoff 
threshold that best distinguishes the long-term outcomes 
between groups. In this analysis, we used Youden’s J 
index, a commonly used measure of overall diagnostic 
effectiveness, to obtain the optimal cutoff points for both 
DpR and ETS. ROC curves of DpR and ETS depicting 
Youden’s J index and optimal cutoff points for PFS or OS 
were constructed (Supplementary Figure 2). Cutoff values 
of 29.3% (PFS) and 27.7% (OS) for ETS and 44.4% (PFS) 
and 43.3% (OS) for DpR were obtained based on the 
highest sensitivity and specificity (Table 3). Cutoff values 
of 30% for ETS and 45% for DpR were chosen for further 
analyses.
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Table 1: Clinicopathologic features and survival outcomes of patients (N = 61)
Characteristics N %
Age
 Median 60
 Range 33–80
Sex
 Male 40 65.6
 Female 21 34.4
ECOG performance status
 0 31 50.8
 1 22 36.1
 2 8 13.1
WHO classification
   Adenocarcinoma well differentiated 5 8.2
   Adenocarcinoma moderately differentiated 37 60.7
   Adenocarcinoma poorly differentiated 14 23
   Signet ring cell 5 8.2
Prior gastrectomy
   Subtotal gastrectomy 8 13.1
   Total gastrectomy 7 11.5
   Not done 46 75.4
Primary tumor location
   Gastroesophageal junction 4 6.6
   Cardia 10 16.4
   Body/Antrum 47 77
HER2 overexpression by IHC
   2+ 15 24.6
   3+ 46 75.4
HER2/CEP17 ratio by SISH or FISH
   2.0-4.69 11 18.0
   ≥ 4.7 11 18.0
   Not determined 39 63.9
Metastatic location
   Lymph node 47 77.0
   Liver 27 44.3
   Peritoneum* 17 27.9
   Lung 8 13.1
   Bone 5 8.2
Chemotherapy regimen
   Herceptin + FP 9 14.8
   Herceptin + XP 52 85.2
Follow-up, months
   Median 24.3
   Interquartile range 18.3–28.3
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Long-term outcome prediction using DpR and ETS
Patients were divided into subgroups according 
to cutoff values for ETS (< 30%: N = 23; ≥ 30%: n = 
38) or DpR (< 45%: N = 24; ≥ 45%: N = 37), and their 
clinicopathological features and survivals were compared 
(Supplementary Table 3). Both groups had similar 
characteristics except for a better performance status and 
higher HER2 overexpression on IHC among the better 
response subgroups. PFS and OS were significantly 
longer for patients in the ≥ 45% DpR group yet not for 
those in the ≥ 30% ETS group. Kaplan-Meier plots for 
PFS and OS in relation to DpR and ETS, each categorized 
by their respective cutoff values, were also constructed 
(Figure 3). Dichotomized DpR was a significant predictor 
of PFS (P = 0.007) and OS (P = 0.006), although ETS 
was not (P = 0.076 for PFS; P = 0.109 for OS). Using 
a multivariable Cox proportional hazards model adjusted 
for potentially confounding prognostic factors such as age, 
ECOG performance status, and HER2 overexpression, it 
was found that the cutoff value of DpR ≥ 45% (vs. < 45%) 
was a significant predictor for OS (median 23.5 vs. 13.1 
months, hazard ratio [HR] = 0.441; 95% CI = 0.204 to 
0.955; Table 4).
Post-progression survival prediction using DpR 
and ETS
Predicting survival after progression is potentially 
useful for selecting patients recommended for second-
line chemotherapy or further clinical trials. For this 
purpose, a subgroup of patients who received second-
line chemotherapy (N = 37) were evaluated for PPS 
and its relation to DpR or ETS. On univariate analysis, 
changes in DpR were significantly correlated with 
PPS (Supplementary Table 4). After adjusting for age, 
ECOG performance status, and HER2 overexpression 
using IHC, DpR was the only independent predictive 
factor for PPS (HR = 0.844; 95% CI = 0.712 to 0.999; 
Supplementary Table 5). The cutoff value of 45% was 
Progression-free survival, months
   Events (Progression or Death) 54 88.5
   Median 8.0
   95% CI 6.8–9.3
Overall survival, months
   Events (Death) 35 57.4
   Median 16.0
   95% CI 11.2–21.0
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; WHO, World Health Organization; 
HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; CEP17, chromosome 17 centromere; SISH, 
silver in situ hybridization; FISH, fluoroscence in situ hybridization; FP, 5-FU+Cisplatin; XP, Xeloda+Cisplatin. *11 patients 
had measurable peritoneal seeding nodules.
Figure 1: Schematic illustration for metrics of tumor size. ETS, early tumor shrinkage; DpR, depth of response; TTG, time to 
tumor growth.
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a significant predictor of patients with longer PPS 
(P = 0.02; Figure 3F).
DISCUSSION
To our knowledge, our study is among the first to 
evaluate DpR as a predictor of long-term outcome and to 
compare the predictive abilities of DpR and ETS in AGC 
patients. Both DpR and ETS were significant predictors 
for PFS and OS in AGC patients who were treated with 
first-line trastuzumab-containing chemotherapy.
We recognized DpR as a novel and effective 
measure of treatment outcome and conducted our study 
to compare DpR with ETS in order to determine which 
tumor-size metric is more predictive of prognosis. In recent 
large randomized phase III trials comparing cetuximab 
in combination with FOLFIRI as first-line treatments in 
colorectal cancer patients [13], the two arms did not show 
a difference in PFS or objective response rate, although 
the OS was longer in the FOLFIRI-plus-cetuximab arm. 
An independent radiological review suggested that the 
increased DpR observed in the FOLFIRI-plus-cetuximab 
Table 2: Multivariable analysis of selected demographic variables
Progression-free Survival Overall Survival
Adjusted for Covariates Adjusted for Covariates
HR 95% CI P HR 95% CI P
Age < 65 Ref Ref
 ≥ 65 0.777 0.423 to 1.426 0.415 1.001 0.482 to 2.069 0.997
ECOG performance status 0 Ref Ref
 ≥ 1 1.746 0.967 to 3.153 0.065 2.284 1.090 to 4.785 0.029
HER2 overexpression by IHC 2+ Ref Ref
 3+ 0.529 0.282 to 0.993 0.048 1.092 0.486 to 2.453 0.832
ETS† 0.858 0.765 to 0.961 0.008 0.869 0.758 to 0.996 0.044
Age < 65 Ref Ref
 ≥ 65 0.796 0.441 to 1.436 0.448 1.119 0.536 to 2.335 0.764
ECOG performance status 0 Ref Ref
 ≥ 1 1.415 0.775 to 2.582 0.258 1.876 0.868 to 4.055 0.110
HER2 overexpression by IHC 2+ Ref Ref
 3+ 0.626 0.333 to 1.179 0.147 1.616 0.671 to 3.891 0.284
DpR† 0.786 0.700 to 0.883 < 0.0001 0.798 0.698 to 0.912 0.001
† HR per 10% tumor size decrease 
Abbreviations: HR, hazard ratio; CI, confidence interval; Ref, Reference; ECOG, Eastern Cooperative Oncology Group; 
HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ETS, early tumor shringkage; TTG, time to 
tumor growth; DpR, depth of response.
Figure 2: Time-dependent receiver operating characteristics curves of DpR and ETS for progression-free survival at 6.7 months* (A) 
and overall survival at 13.8 months* (C); time-dependent integrated AUC of DpR and ETS for progression-free survival (B) and overall 
survival (D). *6.7 months and 13.8 months were chosen from median progression-free survival and median overall survival data reported 
for the Trastuzumab for Gastric Cancer (ToGA) trial. AUC, area under the curve; ETS, early tumor shrinkage; DpR, depth of response.
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arm may explain in part the significant OS advantage 
[16]. This result implies that responses to therapy might 
not be adequately evaluated when performed by only 
using RECIST; however, RECIST-independent tumor-
size metrics such as DpR can better predict or categorize 
patients who will respond to therapy or survive longer. 
As DpR or ETS can easily be calculated from numbers 
obtained through RECIST measurements, DpR can swiftly 
be adopted in future clinical trials as another surrogate 
marker or a secondary end-point and can consequently be 
adopted routinely in clinical practice.
By employing Youden’s J index, we found the 
optimal cutoff values to be 30% for ETS and 45% 
for DpR; however, only the DpR cutoff successfully 
classified patients according to their survival prognosis. 
Our identification of DpR as a dichotomous variable (45% 
cutoff point) makes it easily applicable to clinical practice. 
When adjusted for potential confounding factors, it was 
found that the cutoff value of DpR ≥ 45% (vs. < 45%) was 
a significant predictor for OS yet not for PFS (Table 4). 
This result also supports the notion of using DpR as a 
surrogate marker for OS.
The survival benefit of second-line chemotherapy 
compared to best supportive care has been demonstrated 
in several recent studies in patients with AGC [17–21]. 
Although second-line treatment now represents a standard 
of care in AGC, predictive factors regarding the efficacy 
of second-line chemotherapy are needed, especially 
considering the limited benefit of available therapies. 
Therefore, we examined whether DpR or ETS can 
predict PPS, as that could potentially serve as a guide for 
designing second-line chemotherapy or clinical trials. DpR 
was the only relevant factor in this case; a cutoff value 
of ≥ 45% identified patients with better PPS. Therefore, 
studies examining the efficacy of second-line therapies 
could be stratified according to the DpR achieved during 
first-line therapy. Our results of gastric cancer patients 
on first-line Trastuzumab with DpR ≥ 45% showing 
longer PPS and OS imply that a certain subgroup of 
patients with partial response (response rate ≥ 30%) yet 
without major DpR change (45%) will eventually have 
worse prognosis in terms of PPS or OS. For this group of 
patients, considering the bad prognosis of the advanced 
gastric cancer patients with short PPS, clinicians might 
consider a change to second-line chemotherapy for 
patients on first-line chemotherapy without improvement 
of cancer-related symptoms. Furthermore, the importance 
of DpR in predicting PPS was reported in KRAS wild-
type colorectal cancer patients treated with cetuximab-
based chemotherapy [11], implying that this notion can be 
applied to other tumor types and anti-tumor agents.
As a previous study revealed that TTG was one 
of the metrics that predicted OS in colorectal cancer 
patients receiving cetuximab [12], we re-conducted a 
multivariable analysis with DpR, including TTG as a 
covariate, and confirmed that DpR was a significant 
prognostic factor for survival outcome (Supplementary 
Table 6). One confounding factor was the absolute tumor 
burden. However, when multivariable analyses included 
the adjusted baseline sum of the longest diameters of 
target lesions (tumor burden) as a factor, DpR nevertheless 
remained significantly associated with OS and PFS in our 
study (Supplementary Table 7).
While this study revealed several valuable findings, 
it also had several limitations or arguments. First, this 
study was a retrospective study by design; thus, there may 
have been potential confounding factors in predicting 
long-term survival outcomes. Second, this study had 
a relatively small sample size; however, the patients 
included in this study were very homogeneous, which 
helped to minimize variability in patient prognoses. 
Third, as the patients in this study were treated with both 
trastuzumab and cytotoxic chemotherapy (XP or FP), we 
could not conclude that our results, which demonstrated 
the ability of DpR and ETS to predict prognostic 
outcome in HER2-positive gastric cancer patients, were 
Table 3: Performance indices of early tumor shrinkage and depth of response on long-term outcome
Progression-free Survival Overall Survival
ETS
   Cτ index 0.6722 0.6681
   95% CI† 0.6131 to 0.7807 0.6040 to 0.7952
   Youden Index 0.2516 0.2573
   Cutoff Value 29.3% 27.7%
DpR
   Cτ index 0.6957 0.7191
   95% CI† 0.6564 to 0.8176 0.6694 to 0.8465
   Youden Index 0.2943 0.3056
   Cutoff Value 44.4% 43.3%
†95% CI was obtained from bootstrapping of 1000 samples. 
Abbreviations: ETS, early tumor shrinkage; DpR, depth of response; Cτ, time-dependent concordance; CI, confidence interval.
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Figure 3: Kaplan-Meier curves for progression-free survival (A, B), overall survival (C, D), and post-progression survival (E, F) in 
relation to early tumor shrinkage (cutoff ≥ 30%; A, C, E) and depth of response (cutoff ≥ 45%; B, D, F). ETS, early tumor shrinkage; DpR, 
depth of response.
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attributable to the effect of trastuzumab alone. However, 
the proportion of patients who scored 3+ for HER2 
overexpression by IHC was higher among patients with 
ETS ≥ 30% and DpR ≥ 45% than that of those who scored 
2+ (P = 0.042 and P = 0.003, respectively; Supplementary 
Table 3), suggesting that DpR and ETS are good metrics 
for patients treated with trastuzumab. Additionally, there 
was no statistically significant difference between patients 
who received adjuvant chemotherapy after curative 
gastrectomy (n = 9) and chemo-naive patients (n = 52) 
in terms of PFS (Supplementary Figure 4). This result 
also supports the hypothesis that cytotoxic chemotherapy 
does not have a great effect on the ability of DpR and ETS 
to predict prognostic outcome in HER2-positive gastric 
cancer patients. Even if the results were attributable 
to cytotoxic chemotherapy, this study nevertheless 
highlights the importance of DpR in predicting long-term 
outcomes. Fourth, DpR or ETS were mainly evaluated 
from measurable metastatic sites, some might argue 
that the HER2 tests were mainly performed in primary 
cancer tissues and therefore DpR or ETS may not fully 
reflect the antitumor effect of Herceptin. However, since 
current clinical practice or guidelines do not have any 
recommendation for re-assessment of HER2 status from 
metastatic sites, and since previous studies reported high 
concordance rates of HER2 status between primary gastric 
cancer and paired metastatic sites [22, 23], we think that 
DpR or ETS would reflect anti-tumor effect of Herceptin 
from primary sites. Lastly, as biologically gastric cancer 
in the East differs from that in the West, doubts could be 
raised regarding the applicability of this study’s results 
to gastric cancer patients in the West. Western countries 
have a much higher incidence of gastric cancer that is 
located in the gastroesophageal junction, and there is a 
higher prevalence of diffuse histology in Western gastric 
cancer patients [24]. HER2-positivity rates are higher 
in specimens from the gastroesophageal junction than 
in specimens from the body of the stomach and are also 
higher in the histologically intestinal type than in mixed 
or diffuse types [25]. Less than 10% of the patients in 
this study had gastroesophageal-junction cancer; thus, we 
could not generally adopt our concept of DpR and ETS in 
predicting long-term outcomes in gastric cancer patients 
treated with trastuzumab to patients in the West. However, 
considering that there were no differences in HER2-
positivity between European and Asian countries based on 
Table 4: Multivariable analysis of selected demographic variables and ETS or DpR categorized by 
cutoff values
Progression-free Survival Overall Survival
Adjusted for Covariates Adjusted for Covariates
HR 95% CI P HR 95% CI P
Age < 65 Ref Ref
 ≥ 65 0.816 0.433 to 1.540 0.531 0.945 0.441 to 2.026 0.885
ECOG performance status 0 Ref Ref
 ≥ 1 1.689 0.928 to 3.075 0.086 2.404 1.145 to 5.049 0.021
HER2 overexpression by IHC 2+ Ref Ref
 3+ 0.521 0.274 to 0.993 0.048 0.949 0.429 to 2.100 0.897
ETS < 30% Ref Ref
 ≥ 30% 0.665 0.371 to 1.193 0.171 0.687 0.332 to 1.423 0.312
Age < 65 Ref Ref
 ≥ 65 0.896 0.488 to 1.626 0.720 1.025 0.488 to 2.147 0.950
ECOG performance status 0 Ref Ref
 ≥ 1 1.582 0.861 to 2.915 0.141 2.213 1.045 to 4.675 0.038
HER2 overexpression by IHC 2+ Ref Ref
 3+ 0.587 0.298 to 1.827 0.122 1.224 0.526 to 2.848 0.639
DpR  < 45% Ref Ref
 ≥ 45% 0.609 0.335 to 1.107 0.104 0.441 0.204 to 0.955 0.038
Abbreviations: HR, hazard ratio; CI, confidence interval; Ref, Reference; ECOG, Eastern Cooperative Oncology Group; 
HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ETS, early tumor shrinkage; DpR, depth of 
response
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the ToGA trial screening data (23.9% vs. 23.6%; n = 3665) 
and the Western patients more significantly responded to 
trastuzumab than the Eastern patients in the ToGA trial, 
we expect that DpR and ETS will be significant predictors 
of long-term outcomes among Western gastric cancer 
patients treated with trastuzumab as well.
In conclusion, our results strongly suggest that 
DpR is a significant predictor of long-term outcomes 
including PFS, OS, and PPS among AGC patients 
treated with trastuzumab. We suggest a cutoff value of 
DpR ≥ 45% to identify patients with better prognoses; 
this could guide clinical decision making and further 
identify patients likely to obtain additional benefits from 
trastuzumab or further chemotherapies. Moreover, DpR 
may be a promising and valuable endpoint in designing 
future clinical trials. Further validation of these results in 
prospective trials with larger populations and with other 
tumor types is warranted. 
MATERIALS AND METHODS
Patients and assessments
A single-institution retrospective cohort analysis 
was performed at Yonsei Cancer Center, Seoul, Korea. 
The study included HER2-positive locally advanced, 
recurrent, or metastatic gastric cancer patients who 
were histologically confirmed to be inoperable and had 
been treated with first-line capecitabine plus cisplatin 
(XP) or fluorouracil plus cisplatin (FP) combined with 
trastuzumab. Patients with progression or death events 
before the first scheduled response evaluation time 
were excluded from the study cohort and used in the 
landmark analysis. Patients without measurable lesions 
as defined by the Response Evaluation Criteria in Solid 
Tumors (RECIST) version 1.1 [26] were also excluded. 
Electronic medical records were analyzed retrospectively 
in accordance with the Declaration of Helsinki. The 
Institutional Review Board in Severance Hospital, Seoul, 
Korea, reviewed and approved this study (IRB approval 
Number: 4-2014-1076).
Tumor samples were deemed HER2-positive if 
their HER2 scores were 3+ on IHC or if they stained 
positive for HER2 on silver in situ hybridization (SISH) 
or fluorescence in situ hybridization (FISH; HER2:CEP17 
ratio ≥ 2). Two independent radiologists blinded to patient 
data assessed target lesion responses at various time points 
using computed tomography (CT) according to RECIST 
version 1.1 every two cycles until disease progression or 
withdrawal. The relative change in the sum of the longest 
diameters of target lesions at the first response evaluation 
compared to baseline was defined as ETS. DpR was 
defined as the relative change in the sum of the target 
lesions’ longest diameters at their smallest attained sizes 
compared to baseline (TTG; time to tumor growth). PFS 
was defined as the interval between the first trastuzumab 
administration and the first documentation of progression 
or death; OS was calculated as the time between first 
trastuzumab administration and death of any cause. PPS 
was defined as the survival difference between OS and 
PFS (PPS = OS − PFS).
Statistical analysis
Survival probabilities were estimated using the 
Kaplan-Meier method, and a log-rank test was used to 
evaluate differences between survival curves. A Cox 
proportional hazards regression model was used for 
univariate and multivariable analyses. Multivariable time-
dependent concordance (C
τ
) indices and area under the 
curve (AUC) values for long-term outcomes were obtained 
from time-dependent receiver operating characteristics 
(TDROC) curve analyses to evaluate sensitivity and 
specificity [27]. Nonparametric bootstrapping with 1000 
replicates was used to determine the 95% confidence 
intervals (CIs) of the C
τ
 indices. Youden’s J index was 
calculated to determine the threshold point at which 
to dichotomize the patient population based on DpR or 
ETS in order to predict the PFS or OS [28]. All P-values 
were two-sided, and P < 0.05 was considered statistically 
significant.
SPSS version 20 was used for survival analysis 
via the Kaplan-Meier method. The statistical software 
package R version 13.0 was used to run all other analyses 
including TDROC and the Cox proportional hazards 
regression model.
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